TY - JOUR
T1 - Mutational profile of GNAQQ209 in human tumors
AU - Lamba, Simona
AU - Felicioni, Lara
AU - Buttitta, Fiamma
AU - Bleeker, Fonnet E.
AU - Malatesta, Sara
AU - Corbo, Vincenzo
AU - Scarpa, Aldo
AU - Rodolfo, Monica
AU - Knowles, Margaret
AU - Frattini, Milo
AU - Marchetti, Antonio
AU - Bardelli, Alberto
PY - 2009/8/31
Y1 - 2009/8/31
N2 - Background: Frequent somatic mutations have recently been identified in the ras-like domain of the heterotrimeric G protein α-subunit (GNAQ) in blue naevi 83%, malignant blue naevi (50%) and ocular melanoma of the uvea (46%). The mutations exclusively affect codon 209 and result in GNAQ constitutive activation which, in turn, acts as a dominant oncogene. Methodology: To assess if the mutations are present in other tumor types we performed a systematic mutational profile of the GNAQ exon 5 in a panel of 922 neoplasms, including glioblastoma, gastrointestinal stromal tumors (GIST), acute myeloid leukemia (AML), blue naevi, skin melanoma, bladder, breast, colorectal, lung, ovarian, pancreas, and thyroid carcinomas. Principal Findings: We detected the previously reported mutations in 6/ 13 (46%) blue naevi. Changes affecting Q209 were not found in any of the other tumors. Our data indicate that the occurrence of GNAQ mutations display a unique pattern being present in a subset of melanocytic tumors but not in malignancies of glial, epithelial and stromal origin analyzed in this study.
AB - Background: Frequent somatic mutations have recently been identified in the ras-like domain of the heterotrimeric G protein α-subunit (GNAQ) in blue naevi 83%, malignant blue naevi (50%) and ocular melanoma of the uvea (46%). The mutations exclusively affect codon 209 and result in GNAQ constitutive activation which, in turn, acts as a dominant oncogene. Methodology: To assess if the mutations are present in other tumor types we performed a systematic mutational profile of the GNAQ exon 5 in a panel of 922 neoplasms, including glioblastoma, gastrointestinal stromal tumors (GIST), acute myeloid leukemia (AML), blue naevi, skin melanoma, bladder, breast, colorectal, lung, ovarian, pancreas, and thyroid carcinomas. Principal Findings: We detected the previously reported mutations in 6/ 13 (46%) blue naevi. Changes affecting Q209 were not found in any of the other tumors. Our data indicate that the occurrence of GNAQ mutations display a unique pattern being present in a subset of melanocytic tumors but not in malignancies of glial, epithelial and stromal origin analyzed in this study.
UR - http://www.scopus.com/inward/record.url?scp=69949119638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69949119638&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0006833
DO - 10.1371/journal.pone.0006833
M3 - Article
C2 - 19718445
AN - SCOPUS:69949119638
SN - 1932-6203
VL - 4
JO - PLoS One
JF - PLoS One
IS - 8
M1 - e6833
ER -